KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Receivables (2016 - 2022)

TherapeuticsMD filings provide 13 years of Receivables readings, the most recent being $32.2 million for Q3 2022.

  • On a quarterly basis, Receivables fell 14.02% to $32.2 million in Q3 2022 year-over-year; TTM through Sep 2022 was $32.2 million, a 14.02% decrease, with the full-year FY2021 number at $36.2 million, up 11.72% from a year prior.
  • Receivables hit $32.2 million in Q3 2022 for TherapeuticsMD, down from $45.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $45.8 million in Q2 2022 to a low of $5.1 million in Q1 2018.
  • Median Receivables over the past 5 years was $24.1 million (2020), compared with a mean of $24.1 million.
  • Biggest five-year swings in Receivables: soared 226.75% in 2019 and later fell 14.02% in 2022.
  • TherapeuticsMD's Receivables stood at $11.1 million in 2018, then skyrocketed by 120.5% to $24.4 million in 2019, then skyrocketed by 32.74% to $32.4 million in 2020, then rose by 11.72% to $36.2 million in 2021, then dropped by 11.11% to $32.2 million in 2022.
  • The last three reported values for Receivables were $32.2 million (Q3 2022), $45.8 million (Q2 2022), and $35.4 million (Q1 2022) per Business Quant data.